Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQMV9F)

• Drug Name: Apaxifylline Drug Info
• Synonyms: BIIP-20; U-98950; BIIP-20-XX

Indication

Disease Entry	ICD 11	Status	REF
Cognitive impairment	6D71	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 60949
  CAS Number: CAS 151581-23-6
  TTD Drug ID: DMQMV9F

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[3]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[4]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[5]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[6]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[7]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[8]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[7]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[9]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[10]
INO-8875	DMKNA94	Glaucoma/ocular hypertension	9C61	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Antagonist	[2]

References

• [1] Xanthines as Adenosine Receptor Antagonists. Handb Exp Pharmacol. 2011; (200): 10.1007/978-3-642-13443-2_6.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
• [3] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [4] Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
• [5] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [6] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [7] Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
• [8] Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
• [9] A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
• [10] Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.
• [11] INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. J Pharmacol Exp Ther. 2013 Jan;344(1):59-67.